Check out the latest updates from Cinclus Pharma
Highlights from the 2024 Annual Report: Interview with the founders. Cinclus Pharma, founded by a team of experts with deep roots in the pharmaceutical industry, is on a mission to bring an effective GERD treatment, linaprazan glurate, to the market. Building on groundbreaking work done at AstraZeneca.
Read more
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma. Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Read more
Highlights from the 2024 Annual Report: Interview with Nina Rawal. Trill Impact Ventures views Cinclus Pharma as a strong Life Science candidate with the potential to address unmet medical needs in GERD and H. pylori. Nina Rawal, Co-Head of Ventures and a board member at Cinclus Pharma, contributes her biomedical expertise and financing experience.
Read more